THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen, Inc. (NASDAQ: AMGN) today announced that it had received interim results from the independent investigator-sponsored “PREPARE” study, an open-label, randomized, multicenter Phase 3 study of Aranesp® (darbepoetin alfa) in 733 neoadjuvant breast cancer patients receiving dose-dense, dose-intense preoperative chemotherapy compared to a standard preoperative chemotherapy regimen.
